Investors
Join us in reshaping the future of healthcare.
By investing in Pirche, you’re not just supporting a company—you’re investing in a future where technology and compassion converge to save lives.
Strategic Partnership with tcbalance: Extending the Financing Campaign
Pirche is pleased to announce a significant strategic collaboration with tcbalance Biopharmaceuticals, a pioneering leader in cell therapeutics. This partnership represents a major advancement, as it opens a direct participation for Pirche to the rapidly growing allogeneic cell therapy market and expanding the company’s business opportunities. Pirche Founder and CEO Thomas Klein says:
"The exclusive Pirche technology will be used for the first time in the development of allogeneic cell therapies and the 'off-the-shelf' selection using immune risk profiles in the areas of severe diseases. This is a significant step for Pirche towards the wider business of digital therapeutics. In light of this exciting development and its potential to significantly enhance Pirche's growth trajectory, the financing campaign has been extended by two additional weeks. This extension allows more investors the opportunity to participate in this groundbreaking venture as the company moves into a new and promising business field."
Investments in Pirche via the crowdfunding platform INVESDOR open on August 1, 2024 and will now close at 11:00 PM on September 4, 2024.
During the investment period, you indicate the amount of money you wish to invest and complete all necessary steps accordingly.
- Click on “Invest now”
- Choose the amount of shares you would like to buy
- Click on “Check & Submit your investment”
- Login with your Invesdor account or register for free by clicking on “Sign up for free”
- You can now download the legal documents or have them sent to you by email
- After studying the documents, go back to Invesdor and confirm your investment
- After reading and accepting the information of the checkboxes, click on “Submit binding investment”
After the investment period closes, you are granted a 14-day withdrawal period during which you can still withdraw your offer. This period runs until September 20, 2024. If you have not paid for the share(s) by September 20, 2024, the investment will be rejected and cancelled.
Pirche’s pioneering technology not only enhances patient outcomes but also drives cost efficiencies and operational success for healthcare providers. Our robust IP portfolio and strategic partnerships position us at the forefront of medical innovation.
Product offerings
Kidney
Liver
Heart
Lung
Pancreas
Donor Recipient Risk Assessment
Immune risk stratification
Re-transplant evaluation
Xenotransplantation analysis
Living and deceased donor matching
Post-transplant Care
de novo DSA (donor specific antibody)
Rejection episodes
Post-transplant immunosuppression selection
Infectious disease management
End organ failure
Post-transplant lab testing frequency
Transplant medication therapy selection
Commercial
Commercially available SaaS agreements
US retrospective studies
Pediatric population use
US prospective studies
COMPANY TIMELINE
PATIENT ADVOCACY
Partnering with patient advocacy groups allows Pirche AG to develop more effective, patient-centered technologies, improve transplant outcomes, build trust, gain diverse insights, navigate regulatory challenges, and raise awareness.
Patient-Centric Development
Improved Outcomes
Enhanced Trust and Credibility
Access to Broader Perspectives
Regulatory and Ethical Support
Awareness and Education
